Search Results
Non-Hispanic Black Individuals and Vascular Function
This study will examine the impact of age, sex, and racial/ethnic background on vascular function.
There will be three (3) in-person visits: one screening, one experimental visit, and one visit to return equipment. Equipment includes a 24-hour Ambulatory Blood Pressure monitor and an 8-day accelerometer (physical activity tracker). Blood will be drawn at the screening and experimental visit. Participants will undergo tests for cardiovascular measures during the experimental visit.
$100
Male or Female
Identify as Non-Hispanic Black or Non-Hispanic White
Tobacco consumption (e.g., smoking) or Recreational drug use (e.g., marijuana)
Pregnant and/or breastfeeding
Taking blood pressure medication
Diagnosed with metabolic and/or cardiovascular disease(s)
Oxidative Stress and Harmful Constituent Levels Associated with Little Cigars
The propose of this voluntary research study is to look at the effect of little cigars on biomarkers of potential harm with a focus on oxidative stress and inflammation. The study is also interested the effect of flavors in little cigar.
Subjects will attend 7 study visits over 7 weeks. They will be sent home with a selection of little cigars to use during the first week. Starting at week 2, they will be asked to smoke a certain cigar each week for the next 6 weeks at their study visit. They will be asked to answer a series of questionnaires and to provide biosamples (Exhaled Carbon Monoxide, Exhaled Breath Condensate, Buccal Cells, Urine and Spirometry).
600
Daily tobacco smoker
No serious quit attempts in previous 30 days
Respiratory diseases
Substance Abuse
Understanding Suicide and Self-Harm Among Young Adults in Daily Life
This study explores participants mood and how it changes from day to day and how mood and other things like personality and relationships influence thoughts of suicide or self-harm. Participants will both track and be able to visualize their mood and other experiences on a daily basis from their own smartphones.
There will be a set of questionnaires to complete online that will last between 45 and 90 minutes. Then participants will complete very brief (about 2 minute) surveys a few times per day on their smartphone over 12 weeks.
$140
Undergraduate student at Penn State
Have thoughts of suicide or self-harm in the past 12 months
Own and use an Apple iOS or Android smartphone device
Not a Penn State undergraduate student
Does not own an Apple iOS or Android smartphone device
Unwilling/unable to download and utilize study smartphone app
Studying speech perception in realistic listening conditions
The purpose of this study is to examine how various factors, such as the acoustics of the environment and background noise, affect the understanding of speech.
Researchers in the Graduate Program in Acoustics are looking for participants for a study related to speech intelligibility and room acoustics. The experiment will take approximately 1.5-2 hours of your time. The experiment will consist of listening to sentences and transcribing them under different acoustic and noise conditions. Your head movement will also be measured through a motion sensor. The compensation for your voluntary participation is a $25 Amazon gift card.
$25 Amazon gift card
native speaker of American English
no diagnosed speech, language, or hearing disorders
normal or corrected-to-normal vision
not a native speaker of American English
diagnosed with speech, language, or hearing disorders
not have normal or corrected-to-normal vision
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (PSCI# 21-115) (EAA173).
The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period of time in which patients are free of multiple myeloma symptoms differs between the two treatment groups.Daratumumab is already approved by the FDA for use in combination with lenalidomide and dexamethasone in people who have received at least one prior medicine to treat multiple myeloma. It is not, however, approved for treatment of smoldering multiple myeloma, either alone or when combined with the treatment regimen of lenalidomide and dexamethasone, and therefore is considered experimental. Lenalidomide and dexamethasone are approved for treatment of multiple myeloma (symptomatic) but not for the treatment of smoldering multiple myeloma and therefore is also considered an experimental treatment.
We are asking you to take part in a research study because you have high-risk smoldering multiple myeloma. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.
Patient must be diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 12 months.
A bone marrow aspirate and/or biopsy is required to be performed within 42 days prior to randomization and must demonstrate 10-59% clonal plasma cells.
Patient must have adequate organ and marrow function.
Patient must agree to register into the mandatory REMS program and be willing and able to comply with the requirements of REMS.
Concurrent use of erythropoietin is not allowed while on study therapy.
Prior or glucocorticosteroid therapy for the treatment of multiple myeloma is not permitted.
Patients with monoclonal gammopathy of undetermined significance are not eligible.
Patient must not have Grade 2 or higher peripheral neuropathy per CTCAE.
Habitual Diet and Avocado Trial
This study aims to evaluate the effect of providing one avocado per day for consumption over a six month period on established health parameters, including visceral adiposity, hepatic lipid content, markers of metabolic syndrome and high sensitivity C-reactive protein (hsCRP), compared to habitual diet.The primary aim of this study is to determine whether providing one avocado per day for consumption for six months will produce a greater decrease in visceral adiposity as measured by magnetic resonance imaging (MRI) in Americans with an increased waist circumference as compared to habitual diet.
not currently eating >2 avocados per month
increased waist circumference (35+ inches for women, 40+ inches for men)
not willing to undergo MRI scans
unstable medical conditions
lost/gained 10 or more pounds in past year
ABTECT-2 Induction-A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
This is a multicenter, randomized, placebo-controlled Induction study to evaluate the efficacy and safety of oral ABX464 given daily in inducing clinical remission in subjects with moderately to severely active ulcerative colitis (UC) who have inadequate response, no response, a loss of response, or an intolerance to either conventional or advanced therapies.The screening period is 28 days long, and a 28-day follow-up follows 8 weeks of induction treatment. Approximately 612 subjects (only adults at our site) will be randomized in this study. On Day 1, subjects will be randomized to one of the three arms. On Day 56, subjects can either continue participation in the maintenance study (ABX464-107) or end the study by entering four-week safety follow-up. Colonoscopy procedures will include biopsies of the most severely affected areas. The subjects will complete daily electronic Diaries. Blood samples will be collected at some visits. A cardiac safety sub-study is optional for eligible subjects.
Participants will be asked to sign the informed consent. There are at least five in-person visits, approximately every four weeks. There are two colonoscopy procedures with biopsies: first during the screening period and second evaluation at week 56 at the end of the study. Physical examination and vital signs will be taken at every visit. Stool sample for pathogens will be collected at screening. Blood tests will be taken to test for infectious diseases and other tests. There is an optional cardiac safety study. Pregnancy testing is required for eligible female subjects at every visit. Subjects will complete e-Diary questionnaires. There will be two eye exam visits. Participation in the study is voluntary.
Subjects will receive a flat amount per completed visit, up to maximum of $425.
must understand, sign and date the written voluntary informed consent.
Documented diagnosis of UC confirmed by endoscopy and histology
Inadequate response to immunosuppressants or treatment with biologics
Male partners and women WOCBP must agree to use highly effective contraception methods.
Subjects with CD or subjects with heart disease, or history of malignancy
History or current evidence of toxic megacolon, fulminant colitis, bowel perforation.
Recent or planned bowel surgery.
Subjects on antidiarrheals and probiotics.
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312(Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
This phase 3b study will evaluate long-term safety and efficacy ofCSL312 (also known as garadacimab) when administeredsubcutaneously (SC) once monthly for at least 12 months.Subjects entering CSL312_3002 will be from 3 sources:• Subjects who participated in Study CSL312_2001• Subjects who participated in Study CSL312_3001• CSL312-naïve HAE subjects who have not participated ineither of the above studies
During the study, you will be expected to self-administer the study medication by injection under the skin once a month, complete a daily diary, provide blood and urine samples, complete questionnaires, undergo physical exams and have your vital signs recorded.You will visit the site 12 times.
$80.00 plus travel reimbursement
Male or female
Diagnosed with clinically confirmed C1-INH HAE
Experienced ≥ 3 HAE attacks during the 3 months before Screening, as documented in the subject's medical record.
Aged ≥ 12 at the time of providing written informed consent or assent for minors
Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis against HAE attacks at least 2 weeks before the first day of the Run-in Period.
Use of mAbs such as lanadelumab (Takhzyro®) 3 months before the first day of the Run-in Period.
Female subjects’ use of estrogen-containing medications with systemic absorption (eg, oral contraceptive or hormonal replacement therapy within 4 weeks prior to the Run-in Period).
Female or male subjects who are fertile and sexually active not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 3 months after receipt of the last dose of CSL312.
Impact of Mental Illness on Blame Attribution and Perception of Dangerousness in Violent Crime Offenders: Implications for Sentencing
This study will be used for an undergraduate honors thesis, focused on mental health’s impact on perceived blameworthiness and dangerousness of violent crime offenders and sentencing suggestions for said offenders. In this study, participants will read a vignette about a crime (homicide or assault) being committed. After reading this scenario, participants will answer 4 questions about the individual who committed the crime. These questions will ask about blame attribution, sentencing suggestions, danger perception and likelihood of reoffending. The data will be analyzed through quantitative techniques.
Participants will read a vignette about a crime (homicide or assault) being committed. After reading this scenario, participants will answer 4 questions about the individual who committed the crime. These questions will ask about blame attribution, sentencing suggestions, danger perception and likelihood of reoffending. Participants will then answer one question about their gender and one question about the school year.
Undergraduate students at Pennsylvania State University Park under the age of 18
Identifying the Cognitive, Psychological, and Neuroimaging Signatures of Head Trauma in Female Survivors of Intimate Partner Violence
We aim to investigate the impact exposure to head trauma in intimate partner violence (IPV) has on cognitive, psychological, and neural processes. Physical trauma as an outcome of IPV impacts an estimated 10 million people in the United States each year, with up to 90% of women exposed to IPV reporting episodes of abuse with head trauma. Women exposed to IPV are at a high-risk for developing mental illness and impaired cognitive function, which seems to be compounded in those with exposure to head trauma (HT).
The study includes interviews to discuss your any experiences you have had with physical abuse and head trauma, as well as current and past mental health history. Then you will complete questionnaires to see how you feel about your mental and physical health, followed by tests to assess your thinking abilities. Finally you will complete a magnetic resonance imaging (MRI) session to examine brain structure and function. All of the testing should take approximately 6 hours to complete.
$90
Aged 18-60
Has previously experienced intimate partner violence
Currently experiencing intimate partner violence (within the past 3 months)
Non-English speaker
Neurological and developmental disorders
PSCI# 19-005 EA9161
The is a drug study to compare the progression freesurvival of the three drug combination Ibrutinib-Obinutuzumab-Venetoclax (IOV) to Ibrutinib-Obinutuzumab (IO) in untreated CLL patients younger than 70 years of age.
pt will either get ibrutinib and obinutuzumab, plus venetoclax for up to 19 months or will get ibrutinib and obinutuzumab until doctor decides disease is getting worse or the side effects become too severe. After 19 cycles completed, doctor will follow condition every 90 days until progression and watch for side effects. They will check pt every 3 months for 2 years. After that, they will check pt every 6 months for 3 years. After that, they will check pt every 12 months for 5 years
Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy
Age ≥ 18 years and < 70.
ECOG performance status between 0-2.
Life expectancy of ≥ 12 months.
No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment.
No current use of corticosteroids.
No previous autoimmune complications
No other active primary malignancy
Effects of COVID-19 on Perceptions of Distance
This is a survey that will examine how different factors effects the perceived interpersonal distance between figures https://pennstate.qualtrics.com/jfe/form/SV_9GEF8ubzN3UIOUt
A PHASE 1B OPEN-LABEL/ PHASE 2 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY FOR PHARMACODYNAMIC ACTIVITY, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF KAN-101 IN PATIENTS WITH CELIAC DISEASE-A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease
At this time, there is no treatment available for celiac disease diagnosis. The study is designed to test safety, tolerability and pharmacokinetics of KAN-101 to treat celiac disease diagnosis. We will participate only in the Part C study portion. Part C is a Phase 2, double-blind, placebo-controlled, parallel design study to characterize the biomarker response (plasma IL-2) in peripheral blood following gluten challenge, safety, tolerability, and pharmacokinetics (how does drug move in the body) of KAN-101 in adult participants (18 to 70 years inclusive) with histology-confirmed celiac disease. Participants will be randomized 1:1:1:1, where one arm is placebo, and other arms are different drug doses. The study consists of a screening period to determine eligibility to participate, a run-in phase where participants are gluten-challenged for one day, a treatment phase where participants will receive a seven-days treatment, and observation period lasting 358 days where participants will have a post-dose gluten challenge on Day 15, and three other time-points. The study aims to enroll 120 subjects across all sites. Participants will be asked to come for the clinic visit, to have gluten challenged done in the clinic, and treatment infusions in the clinic. There are two follow-up visits planned. The participants will have required EGD w/biopsy, and will be offered optional EGD biopsy study, that collects specimens at two time points. All participants will have a blood work done to access eligibility for participation, and to test for drug PK and biomarkers in the response of the treatment. They will also have EKG and physical examinations, vital signs checked during the clinic visits. They will complete questions for patient reported symptoms. Eligible women participants will be tested for pregnancy, and contraception will be discussed for both male and female participants.
Participants will be asked to come to the clinic visits for the screening, gluten challenge, treatment visits and follow up. During the visits, participants will have blood tests done to determine eligibility for the study, or the test how the drug moves through the body and whether it works to dampen the celiac disease symptoms. The patients will have EGD with biopsies procedure done in the endoscopy suite, and they will be offered optional biopsies study. The gluten challenge will consist of drinking a glass of water containing 9g pre-prepared gluten challenge mix. The participants will be observed for four hours. The treatment is done via infusion in the clinic over 30-minutes,and observed for four hours after that. The participants will have to come in for three treatment visits within seven days (days 1, 4, and 7).
$1775
positive celiac serology and histology
followed gluten free diet for more than a year
have wheat allergy
have hypersensitivity to gluten
active GI disease
have Type 1 diabetes
Biobehavioral Health Risk and Resilience in College Students (PSU THRIVE Study)
This protocol is designed to examine biobehavioral health risks, resilience, grit, forgiveness and well-being in college students.
18 to 24 years of age
English is a primary language
Under age of 18 years
Over age of 24 years
Not comfortable speaking English
Developing a Recommendation System for Local Community Events
In this study, we investigate a recommender system for public, local events in Centre County, PA. Currently, there is no platform that aggregates all the events that take place in a community. The data is fragmented among many platforms and it can be difficult for people to find interesting things to do. Participants will interact with our software system and discuss their experiences through a survey and/or interview.
Must be a University Park student or local resident of Centre County
Persons who do not live in Centre County, PA
PSCI 24-015 S2212 SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), ARANDOMIZED PHASE III STUDY
To see if participants with early stage triple negative breast cancer randomized to receive anthracycline-free, taxane-platinum neoadjuvant chemotherapy with pembrolizumab have a better breast cancer event-free survival (BC-EFS)compared to participants randomized to taxane-platinum-anthracycline neoadjuvant chemotherapy with pembrolizumab.
keep all study appointmentsreport to your study team any side effects or any changes in medication
Participants must have breast and axillary imaging with mammogram and/or ultrasound and/or MRI within 49 days prior to randomization.
Participants must not have metastatic disease
Participants must not have received prior systemic therapy or radiation therapy
Participants must be ≥ 18 years old.
Participants must not have a prior or concurrent malignancy
Participants must not have received a live vaccine within 30 days prior to randomization.
Participants must not have active autoimmune disease
Participants must not have severe or active infections
Behind virtual world building: Studying virtual reality environmental characteristics
This is a user study to investigate the environmental characteristics of virtual reality (VR). This study will provide empirical evidence of the essential characteristics based on users’ feedbacks. During your visit, you will receive a brief training about using a VR headset and navigating in the virtual environment. After the training, you will explore the virtual environment, complete tasks in VR, and answer questions regarding your feelings to our VR application.
healthy participants
students under 18
students with contagious disease
A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Participants in this study will receive a drug called ribociclib with the endocrine therapy of your physician’s choice. Ribociclib is taken as a pill. Endocrine therapy is taken as a pill or given as a shot. You will have tests, exams and procedures that are part of your regular care and for study purposes. Also, as part of routine care, you will be checked every 4 to 12 weeks to make sure your cancer hasn’t come back. You will receive ribociclib combined with endocrine therapy for up to 3 years. After that you will continue endocrine therapy alone for another 2 years (5 years total) as part of your regular care.
Participants will be required to: - receive ribociclib along with standard endocrine therapy drugs - have blood drawn - imaging scans (CT, PET-CT, bone scans, mammograms, MRI) - keep a medication diary - optional biopsy - ECG-a test that looks at the way your heart beats - ECHO-a test that looks at the way your heart pumps
Male or female age ≥ 18 years at the time of consent.
ECOG Performance Status of 0-1 within 28 days prior to registration.
If patient is receiving tamoxifen or toremifene, a washout period of 28 days prior to registration is required.
Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory.
Patient who has received prior CDK4/6 inhibitor for recurrent disease. Patients who received a CDK4/6 inhibitor in the adjuvant setting may participate if they have been off therapy for at least 1 year prior to diagnosis of recurrent disease.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
Pregnant or breastfeeding or planning to become pregnant during the trial
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety
The Experiences of Asexual Individuals in Health and Sexual Education Classes: Influences on Identity, Body Image, Personal Health, and Patient-Provider Relationships
This project explores the experiences of asexual individuals in health and sexual education classes. Specifically, we are interested in the structure of the courses and the extent to which LGBTQIA+ identities were included in the curriculum. Additionally, we are interested in ways health and sexual education classes have since influenced how asexual individuals view and feel about their bodies, as well as how they approach their personal health. Individuals currently identifying as asexual will be surveyed about their experiences and will have the change to provide recorded interviews if desired.
Participants will be asked to complete an online survey that is expected to take 30-40 minutes. Participants also have the opportunity to elaborate on their survey responses during a recorded Zoom interview.
Participants may enter a raffle to win one of 10 Amazon.com giftcards
Over the age of 18
Took a health/sexual education class in the U.S since the year 2000
Currently identifies as asexual (or an asexual sub-identity)
Under the age of 18
Did not take a health/sexual education class in the U.S since the year 2000
Does not currently identify as asexual (or an asexual sub-identity)
A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
This research is being done to find out the safety of propranolol and, identify the maximum tolerated dose of propranolol that can be administered in combination with pembrolizumab in patients with unresectable stage III and stage IV melanoma. This study will evaluate this novel combination of pembrolizumab and propranolol to see what effect it may have on how your cancer responds to the treatment combination.
Phase II*propranolol twice a day.*pembrolizumab by an infusion every 3 weeks.*May receive treatment with pembrolizumab and propranolol for up to24 months from the time they began treatment with the combination.Procedures to be done:. A medical history A physical exam ECOG Performance Status Perceived Stress Scale questionnaire An assessment of tumor by scan. Scans may include:o Computed tomography (CT), with or without contrast. o Magnetic resonance imaging (MRI) or head CT with IV contrast Blood tests:o Approximately 2 tablespoons for routine testing, such as a complete blood count and acomprehensive metabolic panel Pregnancy test Urinalysis Electrocardiogram A sample of tumor from a previous biopsy or sample taken Phase 1 portion of the study, these evaluations/tests will also occur on Day 8 of Cycle 1 Review concomitant medications. Physical Exams ECOG Performance Status Perceived Stress Scale questionnaire Blood tests:o Every 3 weekso At 3 weeks and 6 months or discontinuation of treatment (whichever comes sooner) and atdisease progressiono Every 3 weeks: Approximately 1 tablespoon for tests that monitor your blood sugar levelsand thyroid functiono Every week for the first 6 weeks then every cycle for another 6 weeks Assessment of cancer by CT or MRI. These assessments will be performed every 12 weeks(± 14 days). The first assessment will be after completing Cycle 4. If their cancer is found to be improving,repeat the CT and MRI scans in about 12 weeks. EKG: Once treatment begins, this will be done every cycle prior to receiving pembrolizumab for the first 5 cycles. Adverse events Tumor Biopsy: A tumor biopsy (only in phase II) will be obtained at the 12 weeks after initiation oftreatment.Tumor biopsy will be optional for phase II patients..Safety Follow-Up:After all study treatment has stopped, end of treatmentvisit, which will be approximately 30 days after their last dose of study drug or before starting a newtreatment Medical History: Concomitant medications complete physical examination ECOG Performance Status Perceived Stress Scale assessment Adverse events Survival status Blood tests:o Follow- Up Phase3 Month and 6 Month Follow- up After Treatment blood collected.The following assessments will be performed at 3 months and 6 months after the safety follow-up visit.Review concomitant medications Physical examination ECOG Performance Status Adverse events Survival Status Blood tests: CT of chest, abdomen and pelvis, or other areas as needed Long Term Survival Follow- Up:After your 3 month and 6 month follow up visits or if they progress, will be contacted every 6 months (±30 days)
Participants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanoma.
Have measurable disease per RECIST v1.1
Have an ECOG performance status 0-1
Participants with chronic autoimmune diseases
Other invasive cancers diagnosed < 3 years back that required systemic treatment. If diagnosed with other invasive cancer ≥ 3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia
Advancing the use of immersive virtual environments to study the effects of racism on eating behavior in an Asian American population
During the COVID-19 pandemic, Asian Americans have faced a rise in overt racism, with thousands of hate incidents reported. This has had a bigger impact on young Asian American adults, leading to emotional distress and health problems. A theory by Harrell suggests that experiencing racial discrimination can harm mental and physical well-being due to stress. Past studies have shown a connection between racial discrimination stress and health issues like obesity and mental disorders. However, there's a need to understand the cultural and emotional factors involved. This research aims to explore how racial discrimination affects Asian Americans' food choices by looking at stress responses and cultural influences. Using surveys, experiments, psychophysiology, and virtual reality, the study will investigate how cultural identity affects stress reactions and subsequent food decisions after racial discrimination experiences.
Hello,We are recruiting Asian Americans with Japanese, Chinese, or Korean heritage for a paid research study.We want to understand how racism affects food choice in a virtual reality (VR) environment. To participate in this study, you will need to complete an informed consent form, and answer questions prior to your arrival at the lab. You will have to come to the lab to watch a video of anti-Asian racism incidents that happened during the COVID-19 pandemic, and answer questions before and after the video. Last, you will make food choices in the VR environment. Participation will require three hours or more of fasting before arrival at the lab.You will be paid $25 in a gift card for your participation. If you come to the lab but do not complete the study, you will still be paid.Please continue to the next page to read the informed consent if you are interested in participating. If you are not, please exit this page.https://redcap.link/lp1wq7uu
$25 Amazon gift card
Aged between 18 and 21 at the start of the study
Born in the US or lived in the U.S. since your 10th birthday or earlier
Self-reported having fasted for at least 3 hours prior to the start of the study
Not aged between 18 and 21 at the start of the study
Not born in the US or not having lived in the U.S. since your 10th birthday or earlier
Self-reported having fasted for less than 3 hours prior to the start of the study
Has epilepsy or a cognitive disability
Effects of atherosclerosis on the autonomic responses to systemic nitric oxide
This research looks at whether atherosclerosis, which is the buildup of fatty deposits in the arteries, affects how nitric oxide works to control blood pressure. Nitric oxide is a substance in the body that helps blood vessels relax and widen. By studying how these two factors interact, we hope to better understand them, which could lead to improved treatments for patients in the future. However, this study does not provide treatment for patients with heart or blood vessel diseases.
You will be asked to participate in one visit and to receive a medication called sublingual nitroglycerin. Various physiological measurements will be recorded during this time including microneurography, blood pressure, heart rate and blood flow.
You will receive $25 per hour for your participation in this research study
Any race or ethnicity
Men and women age 21- 80 years
Capable of speaking English
blood pressure is <160/100 mmHg
Pregnant or nursing women
Incapable of speaking English
Decisional impairment
Patients with diabetes
Understanding the Media Literacy Competencies of Today’s College Students
This study will involve surveying college students regarding their media literacy competencies and experiences with media literacy education.
18 years of age or older
Feasibility and Acceptance of Financial Data Collection in Populations with Bipolar Disorder
Risky financial behaviors during symptomatic episodes of bipolar disorder are included in the diagnostic criteria of this psychiatric illness. Literature has called for granular, longitudinal financial data analysis, although only recently have open banking technologies made this a more realistic possibility. Participaints will be asked to use a data collection application in order to submit financial transaction data via Plaid's open banking API.
In a one-time Zoom session, participants will:--Complete surveys about demographic information and clinical scales related to bipolar disorder. --Interact with an application to securely transfer their deidentified financial records to be compared with clinical scales --Provide insights on their financial behaviors in relation to bipolar disorder, current financial management practices and challenges, and the involvement of others in these management practices
$50
Has a bank account accessible by Plaid API (most financial institutions are supported)
Access to a personal device capable of participating in Zoom calls for orientation and interviews
English-speaking
Currently residing in the US
Major physical illness or cognitive impairment affecting their participation
Lack of access to a personal device capable of participating in Zoom calls for orientation and interviews (e.g., only has access to phone or tablet)
No banking access or unable to access personal web banking features through a financial institution compatible with Plaid API
Non English speaking
The perception and experiences of newly diagnosed type 2 diabetes patients (T2D) on the impact of patient-provider communication on subsequent decision to engage in diabetes self-management education (DSME).
This study seeks to explore the perception and experiences of newly diagnosed type 2 diabetes patients about how their interaction with their provider at diagnosis led to their uptake of diabetes education.
Any gender
Newly diagnosed type 2 diabetes patient within the past 12 months
Have attended at least one diabetes education after diagnosis
Able to provide consent in English
Patients who have a different type of diabetes either than type 2
Patients diagnosed with Type 2 diabetes more than 12 months
Newly diagnosed diabetes patients who have not attended diabetes self-management education
Concussion-Prognosis
Using micro-RNA in saliva coupled with survey data as a prognostic tool with the ability to guide clinical management of concussions
During their baseline visit participants will complete a saliva swab, surveys, balance test and brief neurocognitive test.Day 7, participants will complete a saliva swab and 2 surveys.Day 30, participants will complete a saliva swab and 4 surveys.The baseline visit is the only in-person visit, day 7 and day 30 are done remotely.All surveys are completed online and day 7 and day 30 saliva swabs are sent home with the participants and sent back in a prepaid mailer on day 30.
$40
Diagnosis of concussion
Prospective Cohort Assessing Novel Biomarkers of Early Pregnancy
The purpose of this research is to take and store blood, urine samples from pregnant women diagnosed by a positive pregnancy test or by ultrasound imaging. The purpose of this study is to determine a better way to diagnose the location and/or viability (chance of survival) of a pregnancy, as compared to current clinical care. Many women are found to be pregnant by a hCG (human chorionic gonadotropin) test which detects a hormone that is indicative of pregnancy. However, in early pregnancy, it is often difficult to see the pregnancy by ultrasound, which is called a pregnancy of unknown location (PUL). In early pregnancy, doctors do many tests (including blood tests and ultrasounds) to try to determine how far along the pregnancy is, whether it is healthy, and most importantly whether the pregnancy is growing in the right place. The doctors running this research project are trying to see if there are substances (biomarkers) in the blood or urine of a pregnant woman that can tell whether the pregnancy is a normal, healthy pregnancy, an ectopic pregnancy, or if pregnancy is not viable (miscarriage). To do this, blood and/or urine samples are being collected from women who have a pregnancy of unknown location, an ectopic pregnancy, women who are having a miscarriage, and women with a healthy growing pregnancy. The study will then look at a pre- determined panel of biomarkers that have been shown to be elevated (higher) or decreased (lower) in different types of pregnancy to determine the effectiveness and accuracy of this test in earlier diagnosing the viability and location of early pregnancy.
There will be one visit at the visit participants will be consented and following consenting blood and urine will be collected.
$25.00
Live intrauterine pregnancy through 14 weeks, diagnosed by ultrasound demonstrating fetal heart motion
Diagnosed ectopic pregnancy
Pain or bleeding or at risk for ectopic pregnancy
Women seeking confimation of a pregnancy with a urine or serum pregnancy test (less than 14 weeks)
POSTA: Protocol for Oral Somatosensation and Texture Appreciation
The purpose of this study is to collect normative data related to orofacial (lip/tongue) somatosensation (touch sensation) in healthy adults across the adult lifespan. This data will be compared to a select clinical population, those with Parkinson's disease.
There will be one data collection session lasting approximately 90 minutes. Participants may be invited back for a second session approximately 4 weeks later to repeat the testing sessionDuring the sessions, participants will answer a series of questions about their eating and drinking preferences, they will be asked to provide a speech sample by repeating a series of syllables, words, and sentences, as well as providing a spontaneous speech sample.All participants will be asked to complete a series of sensory tests where small plastic objects are placed on their lip, tongue, and finger tip. Participants will be asked when they feel the pressure/texture and when they do not.
English-speaking
Hearing and cognition within functional limits to complete speaking tasks
Clinical Group: Diagnosed with Parkinson's disease (PD)
have an active lesion to the lower face (ie cold sore, fever blister, etc)
have had a dental visit in the last month that involved general or local anesthesia to the oral region
exhibit symptoms of Tardive Dyskinesia secondary to anti-psychotic drug use
report current or recovering from a viral illness like Bell’s Palsy or Shingles
Linking olfactory deficits to memory impairment and AD neurodegeneration
The purpose of this voluntary research study is to find out more about changes in the brain as we age. This study is trying to determine if magnetic resonance imaging (MRI), genetic variations, amyloid positron emissions tomography (PET), neuropsychological testing, and smell tests can be used to evaluate memory loss and cognitive impairment.
You will be asked to come to the research site once a year for 5 years.Annual (and semi-annual) procedures include completing smell tests, neuropsychological tests, magnetic resonance imaging (MRI). One-time procedures include provide blood sample, amyloid PET scan (if indicated), and optional lumbar puncture.
Up to $250 a year
Smell impairment
Women who are pregnant or breastfeeding
Currently smoke
Have claustrophobia
Mindfulness, Neuroscience and Daily Life Study
This study will examine whether a guided drawing activity helps to reduce anxiety in young adults. This will add to our understanding of how drawing can be used to manage anxiety symptoms and bolster emotion regulation.
This study will require two in person lab visits that take approximately 2 hours each and separated by four weeks where participants will have their brain and heart rate activity monitored while completing mindfulness activities. After the first in person visit, participants will complete two 30 minute audio/questionnaire sessions a week for four weeks (8 total) before returning to the lab for the second visit where participants can expect to complete a similar experience as their first in person visit. Two weeks after the second in person lab visit, participants will complete a Qualtrics questionnaire that will take approximately 30 minutes to complete. Total overall participation of approximately 8 to 8 1/2 hours.
$175
Able to read, speak and write in English
Not able to read, speak and write in English